Durability of Infliximab Dose Intensification in Crohn’s Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Dose intensification is a common approach to treat Crohn’s disease (CD) patients who lose response to infliximab maintenance therapy. Few studies have reported upon its long-term efficacy or predictors of response.
The goal of this study is to investigate durability and predictors of response to dose intensification—including method of dose intensification, combination immunomodulator therapy, and premedication with intravenous hydrocortisone.
We performed a retrospective study of dose-intensified CD patients at our institution. Dose intensification was defined as an increase in dose from 5 to 10 mg/kg, an increase in frequency of infusions from every 8 weeks to every 6 weeks or less, or both an increase in dose and frequency.
Thirty CD patients (mean age, 39.9 years) met study criteria and underwent dose intensification. Ten (33.3%) patients remained on dose intensification at the end of our study or returned to their former infliximab dose or schedule (median follow-up, 41 months). Fourteen patients (46.7%) eventually lost response to dose intensification, but dose intensification extended infliximab therapy by a median duration of 9 months. Six patients (20%) didn’t respond to dose intensification. Neither method of dose intensification, combination immunomodulator therapy, nor premedication with intravenous hydrocortisone predicted initial or durable response to dose intensification. However, analysis of predictors was limited by the small sample size of our study.
The majority of CD patients respond to dose intensification, and a substantial portion will experience durable response such that infliximab therapy is successfully extended by one or more years.
- Hanauer, SB, Feagan, BG, Lichtenstein, GR (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359: pp. 1541-1549 CrossRef
- Schnitzler, F, Fidder, H, Ferrante, M (2009) Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 58: pp. 492-500 CrossRef
- Moss, AC, Fernandez-Becker, N, Kim, KJ (2008) The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s disease. Aliment Pharmacol Ther 28: pp. 221-227 CrossRef
- Rudolph, SJ, Weinberg, DI, McCabe, RP (2008) Long-term durability of Crohn’s disease treatment with infliximab. Dig Dis Sci 53: pp. 1033-1041 CrossRef
- Colombel, JF, Sandborn, WJ, Reinisch, W (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362: pp. 1383-1395 CrossRef
- Gisbert, JP, Panes, J (2009) Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104: pp. 760-767 CrossRef
- Edrees, AF, Misra, SN, Abdou, NI (2005) Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 23: pp. 469-474
- Rahman, MU, Strusberg, I, Geusens, P (2007) Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 66: pp. 1233-1238 CrossRef
- Haraoui, B, Cameron, L, Ouellet, M, White, B (2006) Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 33: pp. 31-36
- D’Haens GR, Panaccione R, Higgins PDR, et al. The London position statement of the world congress of gastroenterology on biologic therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2010; doi: 10.1038/ajg.2010.392.
- Chaparro, M, Martinez, MP, Van-Domselaar, M (2008) Intensification of infliximab (IFX) therapy in 100 patients with Crohn’s disease. Gastroenterology 134: pp. A664
- Regueiro, M, Siemanowski, B, Kip, KE (2007) Infliximab dose intensification in Crohn’s disease. Inflamm Bowel Dis 13: pp. 1093-1099 CrossRef
- Magro, F, Bastos, R, Marques, M (2008) Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis 14: pp. 432-434 CrossRef
- Kopylov, U, Mantzaris, GJ, Katsanos, KH (2011) The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 33: pp. 349-357 CrossRef
- Maser, EA, Villela, R, Silverberg, MS (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4: pp. 1248-1254 CrossRef
- Ternant, D, Aubourg, A, Magdelaine-Beuzelin, C (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30: pp. 523-529
- Baert, F, Noman, M, Vermeire, S (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348: pp. 601-608 CrossRef
- Farrell, RJ, Alsahli, M, Jeen, YT, Falchuk, KR, Peppercorn, MA, Michetti, P (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124: pp. 917-924 CrossRef
- Feagan, BG, Vreeland, MG, Larson, LR (2000) Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 95: pp. 1955-1960 CrossRef
- Odes, S (2008) How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 14: pp. 6641-6647 CrossRef
- Kaplan, GG, Hur, C, Korsenik, J, Sands, BE (2007) Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 26: pp. 1509-1520 CrossRef
- Panaccione, R, Ghosh, S (2010) Optimal use of biologics in the management of Crohn’s disease. Ther Adv Gastroenterol 3: pp. 179-189 CrossRef
- Afif, W, Loftus, EV, Faubion, WA (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105: pp. 1133-1139 CrossRef
- Allez, M, Vermeire, S, Mozziconacci, N (2010) The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 31: pp. 92-101 CrossRef
- Madhusudan, G, Hans, H, Drossman, D (2009) The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 7: pp. 48-53 CrossRef
- Durability of Infliximab Dose Intensification in Crohn’s Disease
Digestive Diseases and Sciences
Volume 57, Issue 4 , pp 1013-1019
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Dose intensification
- Industry Sectors
- Author Affiliations
- 1. Division of Gastroenterology, Department of Internal Medicine, University of California at San Francisco, San Francisco, CA, USA
- 2. Center for Colitis and Crohn’s Disease, University of California at San Francisco, 2230 Post Street Suite 610, San Francisco, CA, 94115, USA